Emerging targets in human lymphoma: targeting the MYD88 mutation

James Q Wang,* Yogesh S Jeelall,* Keisuke Horikawa* Department of Immunology, The John Curtin School of Medical Research, Australian National University, Canberra, ACT, Australia *All authors contributed equally to this manuscript Abstract: B cell neoplasms co-opt the molecular machinery of normal B...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Wang JQ, Jeelall YS, Horikawa K
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/ff4e0887c6a4423ab1ae6b7efdc73c1c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ff4e0887c6a4423ab1ae6b7efdc73c1c
record_format	dspace
spelling	oai:doaj.org-article:ff4e0887c6a4423ab1ae6b7efdc73c1c2021-12-02T00:33:22ZEmerging targets in human lymphoma: targeting the MYD88 mutation1179-9889https://doaj.org/article/ff4e0887c6a4423ab1ae6b7efdc73c1c2013-08-01T00:00:00Zhttp://www.dovepress.com/emerging-targets-in-human-lymphoma-targeting-the-myd88-mutation-a14017https://doaj.org/toc/1179-9889James Q Wang,* Yogesh S Jeelall,* Keisuke Horikawa* Department of Immunology, The John Curtin School of Medical Research, Australian National University, Canberra, ACT, Australia *All authors contributed equally to this manuscript Abstract: B cell neoplasms co-opt the molecular machinery of normal B cells for their survival. Technological advances in cancer genomics has significantly contributed to uncovering the root cause of aggressive lymphomas, revealing a previously unknown link between TLR signaling and B cell neoplasm. Recurrent oncogenic mutations in MYD88 have been found in 39% of the activated B cell-like subtype of diffuse large B cell lymphoma (ABC DLBCL). Interestingly, 29% of ABC DLBCL have a single amino acid substitution of proline for the leucine at position 265 (L265P), and the exact same variant has also been identified in a number of lymphoid malignancies. The MYD88 L265P variant was recently identified in 90% of Wadenstrom's macroglobulinemia patients. These recent developments warrant the need for novel diagnostic tools as well as targeted therapeutics. In this review, we discuss the physiological functions of MYD88 and focus on its role in B cell lymphomas, evaluating the potential for targeting oncogenic MYD88 in lymphoma. Keywords: MYD88, L265P mutation, lymphoma, targeted therapyWang JQJeelall YSHorikawa KDove Medical PressarticleDiseases of the blood and blood-forming organsRC633-647.5ENBlood and Lymphatic Cancer: Targets and Therapy, Vol 2013, Iss default, Pp 53-61 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the blood and blood-forming organs RC633-647.5
spellingShingle	Diseases of the blood and blood-forming organs RC633-647.5 Wang JQ Jeelall YS Horikawa K Emerging targets in human lymphoma: targeting the MYD88 mutation
description	James Q Wang,* Yogesh S Jeelall,* Keisuke Horikawa* Department of Immunology, The John Curtin School of Medical Research, Australian National University, Canberra, ACT, Australia *All authors contributed equally to this manuscript Abstract: B cell neoplasms co-opt the molecular machinery of normal B cells for their survival. Technological advances in cancer genomics has significantly contributed to uncovering the root cause of aggressive lymphomas, revealing a previously unknown link between TLR signaling and B cell neoplasm. Recurrent oncogenic mutations in MYD88 have been found in 39% of the activated B cell-like subtype of diffuse large B cell lymphoma (ABC DLBCL). Interestingly, 29% of ABC DLBCL have a single amino acid substitution of proline for the leucine at position 265 (L265P), and the exact same variant has also been identified in a number of lymphoid malignancies. The MYD88 L265P variant was recently identified in 90% of Wadenstrom's macroglobulinemia patients. These recent developments warrant the need for novel diagnostic tools as well as targeted therapeutics. In this review, we discuss the physiological functions of MYD88 and focus on its role in B cell lymphomas, evaluating the potential for targeting oncogenic MYD88 in lymphoma. Keywords: MYD88, L265P mutation, lymphoma, targeted therapy
format	article
author	Wang JQ Jeelall YS Horikawa K
author_facet	Wang JQ Jeelall YS Horikawa K
author_sort	Wang JQ
title	Emerging targets in human lymphoma: targeting the MYD88 mutation
title_short	Emerging targets in human lymphoma: targeting the MYD88 mutation
title_full	Emerging targets in human lymphoma: targeting the MYD88 mutation
title_fullStr	Emerging targets in human lymphoma: targeting the MYD88 mutation
title_full_unstemmed	Emerging targets in human lymphoma: targeting the MYD88 mutation
title_sort	emerging targets in human lymphoma: targeting the myd88 mutation
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/ff4e0887c6a4423ab1ae6b7efdc73c1c
work_keys_str_mv	AT wangjq emergingtargetsinhumanlymphomatargetingthemyd88mutation AT jeelallys emergingtargetsinhumanlymphomatargetingthemyd88mutation AT horikawak emergingtargetsinhumanlymphomatargetingthemyd88mutation
_version_	1718403717527502848

Emerging targets in human lymphoma: targeting the MYD88 mutation

Ejemplares similares